To investigate the proteomic patterns associated with the response to chemotherapy and targeted therapy, we collected 206 GC patients which received either DOS therapy (DOS subcohort, N = 44, 21.4%), XELOX therapy (XELOX subcohort, N = 70, 34.0%), or anti-HER2-based therapy (HER2 subcohort, N = 71, 34.5%). Here, ERBB2 is linked to gastric cancer.